{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:40:08Z","timestamp":1768318808301,"version":"3.49.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"8","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 A142006"],"award-info":[{"award-number":["R01 A142006"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K01 HL123349"],"award-info":[{"award-number":["K01 HL123349"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,15]]},"DOI":"10.1093\/cid\/cix542","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T11:08:51Z","timestamp":1496920131000},"page":"1274-1281","source":"Crossref","is-referenced-by-count":26,"title":["Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus?"],"prefix":"10.1093","volume":"65","author":[{"given":"Yiannis","family":"Koullias","sequence":"first","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital,"},{"name":"Harvard Medical School,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul E","family":"Sax","sequence":"additional","affiliation":[{"name":"Harvard Medical School,"},{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi F","family":"Fields","sequence":"additional","affiliation":[{"name":"Medical Practice Evaluation Center, Department of Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rochelle P","family":"Walensky","sequence":"additional","affiliation":[{"name":"Harvard Medical School,"},{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, and"},{"name":"Medical Practice Evaluation Center, Department of Medicine and"},{"name":"Division of Infectious Diseases, Massachusetts General Hospital, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily P","family":"Hyle","sequence":"additional","affiliation":[{"name":"Harvard Medical School,"},{"name":"Medical Practice Evaluation Center, Department of Medicine and"},{"name":"Division of Infectious Diseases, Massachusetts General Hospital, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,6,9]]},"reference":[{"key":"key\n\t\t\t\t20180328172648_CIT0001","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"key\n\t\t\t\t20180328172648_CIT0002"},{"key":"key\n\t\t\t\t20180328172648_CIT0003","first-page":"266","article-title":"Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel","volume":"16","author":"Hirsch","year":"2008","journal-title":"Top HIV Med"},{"key":"key\n\t\t\t\t20180328172648_CIT0004","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3851\/IMP1748","article-title":"Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy","volume":"16","author":"Young","year":"2011","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180328172648_CIT0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3851\/IMP1749","article-title":"Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient","volume":"16","author":"Boyd","year":"2011","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180328172648_CIT0006","unstructured":"Rodriquez C , GoujardC, Mercier-DartyM Low frequency of resistance associated mutations by ultra-deep sequencing in HIV-1 primary infected patients [abstract P_47]. In: 14th European Meeting on HIV and Hepatitis, Rome, Italy. Virology Education, 2015:33. Available at: http:\/\/regist2.virology-education.com\/Abstractbook\/2016_4.pdf. Accessed 29 March 2017."},{"key":"key\n\t\t\t\t20180328172648_CIT0007","unstructured":"Volpe JM , YangO, PetropoulosCJ, WalworthCM. Absence of integrase inhibitor resistant HIV-1 transmission in the California AIDS Healthcare Foundation Network. In: Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA, 2015. Available at: http:\/\/www.natap.org\/2015\/ICAAC\/ICAAC_08.htm. Accessed 29 March 2017."},{"key":"key\n\t\t\t\t20180328172648_CIT0008","unstructured":"Margot NA , MartinR, MillerMD, CallebautC. Drug resistance mutations in treatment-naive HIV-infected patients 2000\u20132013 [poster 578]. In: Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, 2014. Available at: http:\/\/www.croiconference.org\/sites\/all\/abstracts\/578.pdf. Accessed 29 March 2017."},{"key":"key\n\t\t\t\t20180328172648_CIT0009","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/jac\/dkv049","article-title":"HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007\u201312: impact on susceptibility to first-line strategies","volume":"70","author":"Frange","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328172648_CIT0010","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1093\/jac\/dkv243","article-title":"Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades","volume":"70","author":"Doyle","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328172648_CIT0011","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3851\/IMP2780","article-title":"Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007\u20132013","volume":"20","author":"Stekler","year":"2015","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180328172648_CIT0012","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/hiv.12414","article-title":"Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom","volume":"18","author":"Tostevin","year":"2017","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20180328172648_CIT0013","unstructured":"Hernandez AL , Banez OcfemiaMC, OsterAM HIV integrase genotypic testing and resistance in the United States\u20149 jurisdictions [poster 478]. In: Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, 2017. Available at: http:\/\/www.croiconference.org\/sites\/default\/files\/posters-2017\/478_Hernandez.pdf. Accessed 29 March 2017."},{"key":"key\n\t\t\t\t20180328172648_CIT0014","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/15284336.2016.1153303","article-title":"Integrase strand transfer inhibitors (INSTIs) resistance mutations in HIV-1 infected Turkish patients","volume":"17","author":"Sayan","year":"2016","journal-title":"HIV Clin Trials"},{"key":"key\n\t\t\t\t20180328172648_CIT0015","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328172648_CIT0016","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328172648_CIT0017","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1086\/652650","article-title":"Late presentation for human immunodeficiency virus care in the United States and Canada","volume":"50","author":"Althoff","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328172648_CIT0018","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/infdis\/jiw165","article-title":"Successful prevention of transmission of integrase resistance in the Swiss HIV Cohort Study","volume":"214","author":"Scherrer","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328172648_CIT0019","volume-title":"Antiretroviral drugs using plasma HIV RNA measurements\u2014clinical considerations for accelerated and traditional approval","author":"Center for Drug Evaluation and Research (CDER)"},{"key":"key\n\t\t\t\t20180328172648_CIT0020","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328172648_CIT0021","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180328172648_CIT0022","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M14-1084","article-title":"Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial","volume":"161","author":"Lennox","year":"2014","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180328172648_CIT0023","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1089\/aid.2008.0254","article-title":"Cost-effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain","volume":"25","author":"Chaudhary","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180328172648_CIT0024","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1478-7547-9-5","article-title":"Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data","volume":"9","author":"Simpson","year":"2011","journal-title":"Cost Eff Resour Alloc"},{"key":"key\n\t\t\t\t20180328172648_CIT0025","volume-title":"Clinical laboratory fee schedule. Code 87901 (infectious agent genotype analysis by nucleic acid [DNA or RNA]) and code 87906 (infectious agent genotype analysis by nucleic acid [DNA or RNA]; HIV-1, other region [eg, integrase, fusion])","author":"Center for Medicare and Medicaid Services"},{"key":"key\n\t\t\t\t20180328172648_CIT0026","volume-title":"Red Book Online"},{"key":"key\n\t\t\t\t20180328172648_CIT0027","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief report: dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328172648_CIT0028","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3018(16)30016-9","article-title":"Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study","volume":"3","author":"Squires","year":"2016","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180328172648_CIT0029","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328172648_CIT0030","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328172648_CIT0031","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/QAI.0b013e318289545c","article-title":"A randomized double-blind comparison of coformulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results","volume":"63","author":"Zolopa","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328172648_CIT0032","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e3181da1287","article-title":"Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses","volume":"55","author":"Lennox","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328172648_CIT0033","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","article-title":"Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial","volume":"4","author":"Sax","year":"2017","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180328172648_CIT0034","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328172648_CIT0035","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1086\/496984","article-title":"Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis","volume":"41","author":"Sax","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328172648_CIT0036","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/QAI.0b013e31824bb720","article-title":"Long-term efficacy and safety of raltegravir, etravirine, and darunavir\/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial","volume":"59","author":"Fagard","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328172648_CIT0037","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1056\/NEJM200010053431401","article-title":"A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators","volume":"343","author":"Lallemant","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328172648_CIT0038","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0140-6736(91)90347-R","article-title":"HIV in pregnant women and their offspring: evidence for late transmission","volume":"338","author":"Ehrnst","year":"1991","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328172648_CIT0039","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/oxfordjournals.aje.a117601","article-title":"Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group","volume":"142","author":"Rouzioux","year":"1995","journal-title":"Am J Epidemiol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/65\/8\/1274\/24267316\/cix542.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T08:54:30Z","timestamp":1659084870000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/65\/8\/1274\/3865792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,9]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,6,9]]},"published-print":{"date-parts":[[2017,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix542","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10,15]]},"published":{"date-parts":[[2017,6,9]]}}}